EcoDrugPlus

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSRFEG00010001125
Gene Symbol: GART
1 Cross references
215 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSRFEG00010015336
Gene Symbol: PLAT
1 Cross references
204 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSRFEG00010007010
Gene Symbol: PTAFR
1 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSRFEG00010004089
Gene Symbol: PDGFRA
1 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSRFEG00010013950
Gene Symbol: PDGFRB
1 Cross references
247 Possible Orthologues:

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSRFEG00010001632
Gene Symbol: PDGFB
1 Cross references
261 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSRFEG00010014727
Gene Symbol: PLK1
1 Cross references
183 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSRFEG00010010126
Gene Symbol: PLK4
1 Cross references
208 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSRFEG00010014181
Gene Symbol: PARP1
1 Cross references
208 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSRFEG00010011619
Gene Symbol: PARP2
1 Cross references
185 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSRFEG00010000961
Gene Symbol: PORCN
1 Cross references
265 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSRFEG00010007791
Gene Symbol: KCNMA1
1 Cross references
284 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).